Merck & Co Inc (MRK) - Financial and Strategic SWOT Analysis Review
Section 1 - About the Company
Merck & Co Inc - Key Facts
Merck & Co Inc - Key Employees
Merck & Co Inc - Key Employee Biographies
Merck & Co Inc - Major Products and Services
Merck & Co Inc - History
Merck & Co Inc - Company Statement
Merck & Co Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Merck & Co Inc - Business Description
Business Segment: Animal Health
Overview
Performance
Business Segment: Other
Performance
Business Segment: Pharmaceutical
Overview
Performance
Geographical Segment: Asia Pacific (other than Japan and China)
Performance
Geographical Segment: China
Performance
Geographical Segment: Europe, Middle East and Africa
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Other
Performance
Geographical Segment: United States
Performance
R&D Overview
Merck & Co Inc - Corporate Strategy
Merck & Co Inc - SWOT Analysis
SWOT Analysis - Overview
Merck & Co Inc - Strengths
Merck & Co Inc - Weaknesses
Merck & Co Inc - Opportunities
Merck & Co Inc - Threats
Merck & Co Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences, Oil & Gas Financial Deals and Alliances
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Merck & Co Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Oct 31, 2024: Merck Announces Third-Quarter 2024 Financial Results
Oct 24, 2024: MSD acquires cancer therapeutics developer Modifi Biosciences
Oct 18, 2024: Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board, Improves Outcomes In Pretreated Patients with Metastatic Cancer
Oct 09, 2024: MSD ventures into fibroblast therapies with $1.9bn deal with Mestag
Oct 03, 2024: Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
Oct 01, 2024: Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
Sep 18, 2024: Linkous Advances Lung Cancer Research with Merck Research Laboratories Scientific Engagement and Emerging Discovery Science Program
Sep 12, 2024: Equitable Breakthroughs in Medicine Development (EQBMED) to Work with Inaugural Sponsor Companies to Drive Greater Diversity in Clinical Trials
Sep 04, 2024: Merck To Present Survival Data And New Research On 10 Investigational Or Approved Medicines At ESMO Congress 2024